• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Unoprostone lowers IOP in advanced glaucoma cases

Article

Washington, DC-Unoprostone isopropyl 0.15% (Rescula, Novartis) may be a viable option for further lowering IOP in patients with advanced glaucoma whose disease is uncontrolled by maximum tolerated medical therapy, said Leslie S. Jones, MD.

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Related Content
SalioGen Therapeutics taps development candidate for ABCA4-mediated Stargardt disease

SalioGen Therapeutics taps development candidate for ABCA4-mediated Stargardt disease

Article
Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures

(EyePod) From idea to impact: Navigating ophthalmic innovation

Podcast
Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy

Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy

Article
EyePod: Modifier Gene Therapy: What is it?

EyePod: Modifier Gene Therapy: What is it?

Podcast
Patients with dry eye suffer from worse sleep quality

Patients with dry eye suffer from worse sleep quality

Article
Ophthalmic industry veteran Erin Schallhorn Powers joins Holland Foundation for Sight Restoration Board of Directors

Ophthalmic industry veteran Erin Schallhorn Powers joins Holland Foundation for Sight Restoration Board of Directors

Article
© 2024 MJH Life Sciences

All rights reserved.